RBC Europe’s Tvardi Therapeutics TVRD Stock Holding History

RBC Europe’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-20	Closed	-$13.8K	–	1178
2018 Q2	$13.8K	Hold	20	–	–	﹤0.01%	769
2018 Q1	$8.9K	Hold	20	–	–	﹤0.01%	861
2017 Q4	$8.8K	Hold	20	–	–	﹤0.01%	860
2017 Q3	$9.84K	Buy	+20	New	+$10K	﹤0.01%	835

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

RBC Europe's TVRD Position: Q3 2018 in Review

RBC Europe sold out of Tvardi Therapeutics (TVRD) in Q3 2018, closing a stake of 20 shares — an estimated $13.8K sold.

RBC Europe first reported a position in TVRD in Q3 2017 and held it in 4 quarters. The position peaked at $13.8K in Q2 2018. 146 funds tracked by Wall St. Rank hold TVRD as of Q3 2018.

RBC Europe reported no remaining Tvardi Therapeutics position as of Q3 2018 after selling out during the quarter.
RBC Europe sold 20 Tvardi Therapeutics shares in Q3 2018, an estimated $13.8K.
RBC Europe first reported a position in Tvardi Therapeutics in Q3 2017 and held it in 4 quarters.
RBC Europe's Tvardi Therapeutics position peaked at $13.8K in Q2 2018.
146 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2018.

Based on RBC Europe's 13F filing for Q3 2018, filed 9 Nov 2023.